These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20569983)

  • 21. A randomized study of alfacalcidol in the refractory myelodysplastic anaemias. A Japanese cooperative study.
    Yoshida Y; Oguma S; Uchino H; Maekawa T; Nomura T
    Int J Clin Pharmacol Res; 1993; 13(1):21-7. PubMed ID: 8509233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
    Heidel F; Cortes J; Rücker FG; Aulitzky W; Letvak L; Kindler T; Huber C; Döhner H; Kantarjian H; Fischer T
    Cancer; 2007 Mar; 109(5):907-14. PubMed ID: 17285599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
    Balleari E; Clavio M; Arboscello E; Bellodi A; Bruzzone A; Del Corso L; Lucchetti MV; Miglino M; Passalia C; Pierri I; Ponassi I; Oneto C; Racchi O; Scudeletti M; Vignolo L; Zoppoli G; Gobbi M; Ghio R
    Leuk Res; 2011 Nov; 35(11):1472-6. PubMed ID: 21794914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
    J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival.
    Crisà E; Foli C; Passera R; Darbesio A; Garvey KB; Boccadoro M; Ferrero D
    Br J Haematol; 2012 Jul; 158(1):99-107. PubMed ID: 22571649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
    Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
    Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome.
    Cordoba I; Gonzalez-Porras JR; Such E; Nomdedeu B; Luño E; de Paz R; Carbonell F; Vallespi T; Ardanaz M; Ramos F; Marco V; Bonanad S; Sanchez-Barba M; Costa D; Bernal T; Sanz GF; Cañizo MC
    Leuk Res; 2012 Mar; 36(3):287-92. PubMed ID: 22133642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.
    Passweg JR; Giagounidis AA; Simcock M; Aul C; Dobbelstein C; Stadler M; Ossenkoppele G; Hofmann WK; Schilling K; Tichelli A; Ganser A
    J Clin Oncol; 2011 Jan; 29(3):303-9. PubMed ID: 21149672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies.
    Bouscary D; Legros L; Tulliez M; Dubois S; Mahe B; Beyne-Rauzy O; Quarre MC; Vassilief D; Varet B; Aouba A; Gardembas M; Giraudier S; Guerci A; Rousselot P; Gaillard F; Moreau A; Rousselet MC; Ifrah N; Fenaux P; Dreyfus F;
    Br J Haematol; 2005 Dec; 131(5):609-18. PubMed ID: 16351636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
    Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
    Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
    Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
    Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amifostine in the treatment of low-risk myelodysplastic syndromes.
    Grossi A; Fabbri A; Santini V; Leoni F; Nozzoli C; Longo G; Pagliai G; Ciolli S; Rossi Ferrini P
    Haematologica; 2000 Apr; 85(4):367-71. PubMed ID: 10756361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
    Ringe JD; Faber H; Fahramand P; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of lenalidomide in myelodysplastic syndromes.
    List A; Kurtin S; Roe DJ; Buresh A; Mahadevan D; Fuchs D; Rimsza L; Heaton R; Knight R; Zeldis JB
    N Engl J Med; 2005 Feb; 352(6):549-57. PubMed ID: 15703420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
    Beran M
    Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.
    Musch E; Malek M; Chrissafidou A
    Ann Hematol; 2003 Apr; 82(4):244-6. PubMed ID: 12707729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Curative effects of cyclosporin A therapy upon myelodysplastic syndrome].
    Chen SC; Jiang B; Da WM; Gong M; Guan M
    Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(38):2711-5. PubMed ID: 17199984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
    Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.